Dentin Dysplasia Type I
Links shared publicly online about this topic
Inovio Pharmaceuticals Achieves Unprecedented T-Cell Immune Responses in Human Trial of DNA Vaccine for Cervical Dysplasia and Cancer Caused by HPV - Drugs.com MedNews
drugs.com — “DNA Vaccine Delivered Using Electroporation Shows Potential to Treat Cervical Cancer and Precursor Dysplasias Vaccine to Start Phase II in Early 2011 Sep 13, 20” View full resource at drugs.com
Most Recently Shared on September 13, 2010 at 1:11 pm By:
Drugs and Devices OW OW Health
Inovio Pharmaceuticals Achieves Unprecedented T-Cell Immune Responses in Human Trial of DNA Vaccine for Cervi... http://bit.ly/bcbyiF #drug
Inovio Pharmaceuticals Achieves Unprecedented T-Cell Immune Responses in Human Trial of DNA Vaccine for Cervical Dysplasia and Cancer Caused by HPV | Business Wire
businesswire.com — “BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18. This vaccine targets HPV E6 and E7 proteins and is delivered” View full resource at businesswire.com
Most Recently Shared on September 13, 2010 at 1:23 pm By:
Inovio Pharmaceuticals Achieves Unprecedented T-Cell Immune Responses in Human Trial of DNA Vaccine for Cervical .... http://bit.ly/c8j5bV
Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study
news-medical.net — “Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18.” View full resource at news-medical.net
Most Recently Shared on September 13, 2010 at 8:42 am By:
Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study: Inovio Pharmaceuticals, Inc., a leade... http://bit.ly/c3w4a0
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
-
OrganizedWisdom HPV
Organizing HPV resources shared by health experts, advocates, and organizations into WisdomCards.
-
News-Medical.Net
Medical News from Around the World
Advertisement
